Acromegaly can be cured by first-line pasireotide treatment?
- 88 Downloads
Pasireotide long-acting release (LAR) is a new generation long-acting somatostatin multi-receptor ligand, with an increased affinity for the five subtypes of the somatostatin receptor compared with first-generation somatostatin analogues (SSAs) . Several studies have proven the efficacy of pasireotide LAR in reaching the biochemical control of acromegaly, both in medically naive and in patients resistant to conventional SSA [2, 3, 4, 5, 6, 7]. We report here the case of a patient with acromegaly who was successfully treated with first-line pasireotide LAR.
The patient’s medical history concerning the present case started on April 2009, at the age of 68 years, when the patient underwent urologic specialist evaluation for a recent occurrence of nocturia, pollakiuria, and dysuria. The specific prostate antigen (PSA) value was normal. However, the ultrasound evaluation of the prostatic gland showed an increased volume of the gland with a transversal diameter of 57 mm. The...
Compliance with ethical standards
Conflict of interest
Medical writing and editorial assistance were provided by Luca Giacomelli, PhD, and Aashni Shah, on behalf of Content Ed Net; this assistance was funded by Novartis Farma (Origgio, Italy). MS is Novartis Farma employee. The remaining authors declare that they have no conflict of interest.
Informed consent was obtained from the individual participant included in the study.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.M.R. Gadelha, M.D. Bronstein, T. Brue et al. Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, Phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875–884 (2014). https://doi.org/10.1016/S2213-8587(14)70169-X CrossRefGoogle Scholar
- 2.M. Sheppard, M.D. Bronstein, P. Freda et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18(3), 385–894 (2015). https://doi.org/10.1007/s11102-014-0585-6 CrossRefGoogle Scholar
- 4.S. Tahara, M. Murakami, T. Kaneko, A. Shimatsu, Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr. J. 64(7), 735–747 (2017). https://doi.org/10.1507/endocrj.EJ16-0624 CrossRefGoogle Scholar
- 5.I. Shimon, W. Saeger, L.E. Wildemberg, M.R. Gadelha, Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Horm. (Athens). 16(1), 84–91 (2017)Google Scholar
- 6.M. Fleseriu, E. Rusch, E.B. Geer, ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55(1), 247–255 (2017). https://doi.org/10.1007/s12020-016-1182-4 CrossRefGoogle Scholar
- 7.M.D. Bronstein, M. Fleseriu, S. Neggers et al. Pasireotide C2305 Study Group. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr. Disord. 16, 16 (2016). https://doi.org/10.1186/s12902-016-0096-8 CrossRefGoogle Scholar
- 8.J.S. Chang, H.M. Tseng, T.C. Chang, Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. J. Formos. Med. Assoc. 115(6), 475–480 (2016). https://doi.org/10.1016/j.jfma.2016.02.003 CrossRefGoogle Scholar
- 9.A.G. Osborn, K.L. Salzman, M.D. Jhaveri, A.J. Barkovich, Sella and pituitary. in Diagnostic Imaging Brain. (Alirsys Elsevier, Philadelphia, 2016), 3, ch 292, pp. 1056–1059Google Scholar
- 12.D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174(2), 241–250 (2016). https://doi.org/10.1530/EJE-15-0832 CrossRefGoogle Scholar